Hani Esmaeilian
A5024665813- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Pneumonia and Respiratory Infections
- Vitamin C and Antioxidants Research
- Infectious Encephalopathies and Encephalitis
- Hepatitis C virus research
- Drug-Induced Hepatotoxicity and Protection
Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico vitro evidence that suggests these agents may also be SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir combination with treating patients COVID-19.Patients a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR or bilateral multi-lobar ground-glass opacity their chest CT signs severe COVID-19 were included. Subjects divided into two arms one arm...
The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies small sample sizes. This larger trial aimed to assess if the addition sofosbuvir/daclatasvir standard care improved clinical outcomes COVID-19.This was a placebo-controlled, double-blind, randomized adults at 19 hospitals Iran. Patients were oral 400/60 mg once-daily or placebo care. included they had positive PCR diagnostic chest CT, O2 saturation...
Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies small sample sizes. This larger trial aimed to assess if the addition standard care improved clinical endpoints hospitalized moderate or severe COVID-19. Methods: was a placebo-controlled, randomized adults admitted 19 hospitals Iran. Patients were SOF/DCV 400/60mg once-daily placebo care. included they had positive PCR diagnostic chest...
Background: Vitamin C is a micronutrient with anti-inflammatory and free radical scavenging properties that can strengthen the body’s immune system. In this study, it was attempted to assess clinical efficiency of oral vitamin in treating COVID-19. Materials Methods: This double-blind randomized trial conducted on 401 patients hospitalized Taleghani hospital, Abadan, over 18 years age confirmed COVID-19 infection, from November 2020 May 2021. The were randomly assigned intervention groups...